At Slipstream Life Sciences we work to streamline IT Support and provide managed solutions with a strategic consulting and global leadership management approach. Our solutions are designed exclusively for emerging pharma and biotech organizations. Slipstream’s industry-leading
Department: Regulatory - TTSGLocation:Rapperswil-Jona (SG), SwitzerlandBe a part of a global team that is inspired to make a difference in the lives of people living with rare disease.At Travere Therapeutics, we recognize that our exceptional employees
Overview In this role you ensure GMP-compliant QA operations for Investigational Medicinal Products, focusing on documentation and quality systems. You will work with CMOs and internal stakeholders to keep batch documentation accurate, inspection-ready, and timely. You
Overview As GPSSL you lead and perform safety surveillance across the product lifecycle, acting as the primary safety owner. You shape safety strategy, drive benefit–risk assessments, and ensure high-quality regulatory deliverables in collaboration with Safety Science
Overview In this senior role, you will lead GCP audit and vendor management to uphold regulatory compliance and quality across clinical trials. You will partner with cross-functional teams to strengthen audit programs, CAPAs, and vendor performance,
Revolution Medicines is seeking a Director, Regulatory Operations, Europe to provide strategic and operational leadership for European regulatory submissions across the EU, EEA, UK and Switzerland. You will own portfolio submission planning, governance, and lifecycle management,
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio